NETRI, an industrial start-up specializing in neuro organs-on-chip combined with AI, announces the acquisition of HCS PHARMA assets. This strategic operation is fully in line with NETRI’s development plan and strengthens its technological offering by integrating patented innovations in biomaterials and advanced cellular models.
NETRI, start-up industrielle spécialisée dans les neuro organes sur puce combinés à l’IA, annonce l’acquisition des actifs de HCS PHARMA. Cette opération stratégique s’inscrit pleinement dans le plan de développement de NETRI et renforce son offre technologique en intégrant des innovations brevetées dans le domaine des biomatériaux et des modèles cellulaires avancés.
Based on a decade of academic research, NETRI continues its ascent with the inauguration of its organs-on-chip production plant in Lyon, a first in France. Accompanied by €5m fund-raising, this new site marks a change of scale for the industrial start-up, which in just six years has become a key player throughout France and internationally, in the field of medical research and healthcare technologies.
Basée sur une décennie de recherche académique, NETRI continue son ascension avec l’inauguration de son usine de production d’organes-sur-puce à Lyon, une première en France. Accompagnée d’une levée de fond de 5 m€, ce nouveau site marque un changement d’échelle pour la start-up industrielle, qui en six ans, est devenue un acteur référent sur l’ensemble du territoire et à l’international, dans le domaine de la recherche médicale et des technologies de santé.
NETRI, an industrial start-up based in Lyon (France), has been awarded the highly coveted Innovation Award from CES Las Vegas for its pioneering platform, NeuroFluidics™ Care. This platform is transforming biochemical safety assessments, enabling early toxicity analysis of compounds used by the food industry with unprecedented precision and accessibility.
The FDA’s Center for Drug Evaluation and Research (CDER) has accepted the first letter of intent (LOI) into its ISTAND Pilot Program for organs-on-chip technology. This LOI is for a human Liver-Chip used to assess the risk of DILI in adults to create relevant data for a drug’s investigational new drug (IND) submission. This LOI acceptance marks a major step forward for CIVM in general.